查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1133479

全球注射用水市场 - 2022-2029

Global Water for Injection Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

注射用水市场的增长是由对特定治疗用途的蛋白质和疫苗等药物需求的增加、医疗设施的快速发展、对仿製药的需求以及癌症和心血管疾病等各种疾病带来的。大约由于越来越流行

增加对药物开发的投资有望推动市场增长

癌症和心血管疾病等各种疾病的患病率上升预计将在预测期内提振市场。水是我们身体组织的重要组成部分，约占我们总重量的70%。正常成人每日需要 2 至 3 升，用于通过汗液和尿液排出的不可接触的液体。无菌注射用水，当作为药物载体肠胃外给药时，在引入足够的溶质以达到每升 112 mol 的渗透压增加后，提供了肠胃外液体补充的来源。此外，最近的市场机会导致服务提供商对先进製造设施进行重大投资。例如，2021年1月，赛默飞世尔科技宣布以8.75亿美元收购诺华赛在比利时的病毒载体製造业务Henogen S.A.，并宣布提供病毒载体製造服务。 Fujifilm Corporation 还向 Fujifilm Diosynth Biotechnologies 投资了约 9.28 亿美元，这是一家生物製剂和先进治疗药物 CDMO。

对药物开发的投资增加导致研究活动增加，这对注射用水市场产生了积极影响。

注射用水成本高阻碍市场增长

但是，与註射用水相关的副作用包括静脉发炎（可能由于注射技术而发生）和注射部位疼痛。此外，长期患有肝肾疾病的患者在开始注射用水前应咨询医生。此外，哺乳母亲不能直接饮用注射用水，这可能会对市场增长产生负面影响。

COVID-19 影响分析

COVID-19 的出现对全球注射水市场产生了重大影响。近年来，主要通过肠胃外给药的复杂癌症疗法和新冠病毒疫苗等生物製剂的不断增长，增加了对先进製造支持的需求，使得合同开发和製造组织 (CDMO) 发挥了重要作用。生物製剂的这种进步为市场上的主要参与者提供了机会。例如，Greenlight Biosciences 和全球 CDMO Samsung Biologics 已合作为三星生物生产大量 Greenlight 的信使 RNA 候选疫苗 COVID-19。该合作伙伴关係旨在推动 Greenlight 的 COVID-19候选疫苗进入 III 期临床试验和批准后的商业销售生产。另一方面，我们面临全球供应链中断、生产设施停工、耗材和材料供应短缺、产能短缺等问题。临床试验经常被取消或推迟。然而，只要 COVID-19 疫情好转，所有开放和受监管的原材料供应链设施都会为製药和生物製药公司创造机会，从而推动市场增长。

全球注射用水市场报告将提供对大约 50 多个市场数据表、50 多个图表和 200 页（大约）的访问。

内容

第一章市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按应用：市场细分
  • 按最终用户：市场细分
  • 按分销渠道：市场细分
  • 按地区：市场细分

第 4 章市场动态

  • 市场影响因子
    • 驱动程序
      • 心血管疾病发病率上升
      • 研究活动增加
    • 限制因素
    • 严格监管
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析
  • 定价分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按应用程序

  • 临床药理学
  • 药物稀释
  • 抗菌用途
  • 其他

第 8 章最终用户

  • 製药公司、生物技术公司
  • 研究所
  • 医院
  • 诊所
  • 其他

第 9 章分销渠道

  • 医院药房
  • 零售药房
  • 在线药店
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 按治疗类型划分的基准

第 12 章公司简介

  • 雅培实验室
    • 公司概况
    • 治疗类型组合和描述
    • 主要亮点
    • 财务摘要
  • AdvaCare Pharma
  • B. Braun SE
  • FUJIFILM Holdings Corp.
  • GlaxoSmithKline Plc
  • Merit Healthcare International Inc.,
  • Novartis AG
  • Pfizer Inc.
  • Pharma Cure Laboratories
  • Sanofi

第 13 章全球可注射水市场-DataM

简介目录
Product Code: DMPH5852

Market Overview

Water for Injection Market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of x% during the forecast period (2022-2029).

Water for Injection (WFI) is a water quality standard described by pharmacopeial groups globally. It is used for many essential pharmaceutical products and applications, including necessary use for hemofiltration, irrigation, injectable drugs, in the production of some active pharmaceutical ingredients, implantable medical devices, and other various applications.

Market Dynamics

The Water for Injection market growth is driven by the rising demand for medicines such as proteins and vaccines for specific therapy, rapid advancement in healthcare facilities, demand for generic formulations, and increasing prevalence of different disease such cancer and cardiovascular disease.

The rising investment in the development of drugs is expected to drive the market growth

The rising prevalence of different diseases such as cancer and cardiovascular diseases is expected to boost the market over the forecast period. Water is a critical component of our body tissues and accounts for around 70% of total body weight. Average normal adult daily requirements range from two to three liters each for insensible water loss by perspiration and urine production. When it is administered parenterally as a vehicle for drugs, sterile water for injection offers a source of water for parenteral fluid replenishment after sufficient solute is introduced to reach an osmolarity of 112 mol per liter. In addition, recent market opportunities have service providers making remarkable investments in advanced manufacturing facilities. For instance, in January 2021, Thermo Fisher Scientific announced its viral vector manufacturing services through the acquisition of Henogen S.A., Novasep's viral vector manufacturing business in Belgium, for $875 million. Also, Fujifilm Corp. invested around $928 million in Fujifilm Diosynth Biotechnologies, a CDMO of biologics and advanced therapies.

Increasing investment in drug development leads to increasing research activities, which positively impacts on water for injection market.

The high cost of water for injection will hamper the growth of the market

However, the side effects related to water for injections such as inflammation of a vein (that may occur due to the technique of injecting) and pain at the injected site. Also, liver and kidney patients with a long history of this disease have to consult their doctor before starting the water for injection. In addition, a nursing mother cannot take water for injection directly this have a negative impact on the market growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global water for injection market. Recently increasing pipeline of biologics, including complex oncology products moslty delivered parenterally, and COVID vaccine production, there is rising demand for technically advanced manufacturing support, in which contract development and manufacturing organizations (CDMOs) are playing a vital role. These advancemnt in biologics provides the opportunity to the key players in the market. For instance, GreenLight Biosciencesand Samsung Biologics, a global CDMO, collaborated, in which Samsung Biologics will manufacture GreenLight's messenger RNA COVID-19 vaccine candidate at large scale. This collaboration aims to drive the production of GreenLight's COVID-19 vaccine candidate for Phase III trials and, it is subject to regulatory approval, commercial sales. On the other hand, global supply chains disruptions, iterupptions in manufacturing facilities, the more companies faced lack of supply of consumables, commodities, and fill-finish capacity. There are many clinical trials were cancelled or postponed. But as far as the situation of COVID-19 is recovering all facilities are opened and regulated supply chains of raw material gives opportunity to pharma and biophrma companies which is drirng the market growth.

Segment Analysis

The pharmaceutical & biotechnology companies segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The pharmaceutical & biotechnology companies segment is expected to boost the market over the period of the forecast. The WFI is essential for drug formulations and other activities in pharma and biotech companies. As per the European medicines agency, 2020 data report, The European Pharmacopoeia provided quality standards for types of water for pharmaceutical use including Purified Water Water for Injections (WFI), and Water for preparation of extracts. The WFI is used in many sterile medicinal products such as biologics, parenteral, haemodiafiltration solutions, peritoneal dialysis solutions, and irrigation solutions. Also, in 2020, Expert Committee on Specifications for Pharmaceutical Preparations (ECSPP), agreed that the monograph mentioned in The International Pharmacopoeia (Water for injections) and the guideline World Health Organization Good manufacturing practices: water for pharmaceutical use is WFI. Moreover, in pharma companies there are so many activities are performed including drug formulation. For instance, in the manufacturing process of injectable products, such as diluting or dissolving drug substances or preparations during the manufacturing of parenteral products, and for the manufacture of water for the preparation of injections. Bulk WFI can be utilized for the end of the cleaning of equipment which is come into contact with injectable products and final rinse to make sure that no subsequent thermal or chemical deproteinization process is applied.

Geographical Analysis

North America region holds the largest market share of the global water for injection market

North America dominates the market for water for injection and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to the presence of a large number of key players, an advanced healthcare system, and rising research and development activities. To develop a drug, there is a need to follow regulatory guidelines such as the United States Pharmacopoeia (USP). In addition, due to technology advancements, the key players are designed to meet the needs of the pharmaceutical industry and provide an inexpensive method for producing WFI. For instance, Evoqua's VRx system offers ease of use, carbon filtration, reverse osmosis, UV light, particle filtration, electrodeionization, and ultra-filtration technologies. The VRx system offers users reliable, high-quality WFI.

Furthermore, the new term coming into the market is "Cold WFI''. It has an ambient temperature of both cold and hot WFI are softened and dechlorinated with RO, but the main difference between both types of WFI systems is that cold WFI systems use a second membrane barrier, such as low-pressure ultrafiltration, to ensure microbiological quality in place of energy-intensive distillation processes.

Competitive Landscape

The water for injection market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Abbott Laboratories, AdvaCare Pharma, B. Braun SE, FUJIFILM Holdings Corp., GlaxoSmithKline Plc, Merit Healthcare International Inc., Novartis AG, Pfizer Inc., Pharma Cure Laboratories and Sanofi among others. The major players are adopting several growth strategies such as Treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the water for injection market globally.

For instance,

  • In July 2021, Nexus Pharmaceuticals launched potassium chloride in water for injection in single-dose IV bags of 10mEq/100mL, 10mEq/50mL, and 20mEq/50mL. This will be available in environmentally friendly cartons of 24 IV bags.
  • In 2022, WuXi STA, has announced its first parenteral formulation manufacturing line at the Wuxi city site. In this manufacturing plant fully automatic sterile manufacturing line operates in a full isolation system with an annual capacity of 2 million units.

B. Braun Medical Inc.

Overview:

B. Braun is a German medical and pharmaceutical device company, founded in 1839 and presence in more than 60 countries. It provides healthcare products and it has an out-patient division.

Treatment type Portfolio:

Sterile Water for Injection: It is a colorless, clear, odorless liquid. It is hypotonic, sterile, nonpyrogenic, and contains no bacteriostatic or antimicrobial agents. It is a diluent or solvent suitable for intravascular injection after first having been made nearly isotonic by the addition of a suitable solute. It is available in different volumes such as 1L, 2L, and 3L, 250mL, and 500 ML.

The global water for injection market report would provide access to approximately 50+ market data tables, 50+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet By Application
  • 3.2. Market Snippet By End User
  • 3.3. Market snippet By Distribution channel
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising incidences of cardiovascular diseases
      • 4.1.1.2. The increasing number of research activities
    • 4.1.2. Restraints:
    • 4.1.3. The stringent regulations
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
    • 7.1.2. Market Attractiveness Index, By Application Segment
  • 7.2. Clinical Pharmacology*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Medication Dilution
  • 7.4. Anti-bacterial Application
  • 7.5. Others

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Pharmaceutical & Biotechnology Companies*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Research Institutes
  • 8.4. Hospitals
  • 8.5. Clinics
  • 8.6. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Treatment type Benchmarking

12. Company Profiles

  • 12.1. Abbott Laboratories*
    • 12.1.1. Company Overview
    • 12.1.2. Treatment type Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. AdvaCare Pharma
  • 12.3. B. Braun SE
  • 12.4. FUJIFILM Holdings Corp.
  • 12.5. GlaxoSmithKline Plc
  • 12.6. Merit Healthcare International Inc.,
  • 12.7. Novartis AG
  • 12.8. Pfizer Inc.
  • 12.9. Pharma Cure Laboratories
  • 12.10. Sanofi

LIST NOT EXHAUSTIVE

13. Global Water for Injection market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us